Joint research agreement on the development of technologies for use in the clinical setting to analyze SNPs using whole blood for personalized medicine
September 1, 2004 PRESS RELEASE
The SRC has entered into a joint research agreement with Toppan Printing Co., Ltd. and Shimadzu Corporation on the development of technologies for use in the clinical setting to analyze SNPs using whole blood for personalized medicine. The joint research will be based on SNP typing system developed by Group Director Yusuke Nakamura at the Research Group for Personalized Medicine.
Under the joint research agreement, Toppan Printing will develop SNP chips using a SNP typing technology based on RIKEN's Multiplex PCR method, while Shimadzu will develop reagents using the PCR pre-processing reagent Ampdirect®. These joint technologies should achieve the rapid SNP testing within 2 hours from blood collection. The goal is to develop SNP testing for use in personalized medicine techniques in the clinical setting, using a completely new analytical method that combines these technologies with the Invader® method developed by Third Wave Technologies, Inc.
Global-standard diagnostic methods must be a key goal for personalized medicine, given the inextricable link between diagnosis and treatment, as well as current moves to develop drugs on a global basis. We have high expectations for the results of such research through the creation of joint industry-academia partnerships with a global perspective.